Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...

Risk of Guillain-Barré syndrome (GBS) increased slightly after receiving the recombinant zoster vaccine (RZV; Shingrix), Medicare claims data showed. In the 42 days after vaccination, researchers ...

The FDA granted Pfizer a breakthrough therapy designation for its group B Streptococcus vaccine candidate for pregnant people to prevent GBS disease in newborns based on its ongoing phase 2 trial. GBS ...

Group B Streptococcus (also known as group B strep or GBS) is a common bacterium found in the rectum, digestive tract, and urinary tract of men and women. It’s also found in a woman’s vagina. GBS ...

Group B Streptococcus, which people may call group B strep (GBS), is a type of bacterium that causes GBS disease. GBS can lead to meningitis, which is an infection of the lining of the brain and ...

Thanks to the relentless efforts of medical researchers around the world, several different messenger ribonucleic acid (mRNA) and vector-based vaccines were authorized for use by regulatory bodies ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy). The ...